Meta-analysis of Clinical Outcomes Comparing Surface Ablation for Correction of Myopia With and Without 0.02% Mitomycin C

ABSTRACT PURPOSE: To evaluate the current clinical evidence of safety and effi cacy of intraoperative topical application of 0.02% mitomycin C (MMC) used for up to 2 minutes after surface ablation for correction of myopia.METHODS: A comprehensive literature search was con-ducted of Cochrane Library, MEDLINE, and EMBASE to identify relevant trials comparing surface ablation for correction of myopia with and without MMC. A meta-analysis was performed on the results of the reports and statistical analysis was performed. RESULTS: Eleven clinical trials were identifi ed with MMC used in 534 eyes and no MMC in 726 eyes. Surface ab-lations with MMC led to signifi cantly less corneal haze in photorefractive keratectomy, whereas the results were comparable in laser epithelial keratomileusis (LASEK) and epithelial laser in situ keratomileusis (epi-LASIK). Although proportionately more eyes in the MMC group achieved uncorrected distance visual acuity 20/25 or better and less frequently lost 2 lines of corrected dis-tance visual acuity, the difference was not statistically signifi cant. CONCLUSIONS: Our meta-analysis suggests that the topical intraoperative application of 0.02% MMC may reduce haze and improve visual acuity after surface ablation for correction of myopia. However, the advan-tage of using MMC in LASEK and epi-LASIK is unclear. [